BlackRock’s InMed Pharmaceuticals INM Stock Holding History

BlackRock’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3	Closed	-$46	–	5495
2023 Q2	$46	Hold	3	–	–	﹤0.01%	5475
2023 Q1	$54	Hold	3	–	–	﹤0.01%	5542
2022 Q4	$101	Buy	+3	New	+$202	﹤0.01%	5721

Other funds holding INM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Gables Capital Management Miami, Florida $277M AUM 41.82% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

BlackRock's INM Position: Q3 2023 in Review

BlackRock sold out of InMed Pharmaceuticals (INM) in Q3 2023, closing a stake of 3 shares — an estimated $46 sold.

BlackRock first reported a position in INM in Q4 2022 and held it in 3 quarters. The position peaked at $101 in Q4 2022. 8 funds tracked by Wall St. Rank hold INM as of Q3 2023.

BlackRock reported no remaining InMed Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
BlackRock sold 3 InMed Pharmaceuticals shares in Q3 2023, an estimated $46.
BlackRock first reported a position in InMed Pharmaceuticals in Q4 2022 and held it in 3 quarters.
BlackRock's InMed Pharmaceuticals position peaked at $101 in Q4 2022.
8 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q3 2023.

Based on BlackRock's 13F filing for Q3 2023, filed 13 Nov 2023.